We found evidence for a difference of case related costs of inpatient treatments for paranoid
SZ and SAD. The differences in mean total costs seem to be primarily related to the mean
personnel costs in patients with paranoid SZ and SAD rather than mean pharmaceutical
costs, possibly due to higher personnel effort and infrastructure.